Cell Health and Energy Metabolism

Protein-Protein Interaction

Safety/Toxicology

Cardiovascular Disease

GPCR

Ion Channel

Enzymatic Assay

New Screening Technology

Antibody

Optogenetic

High Speed Acquisition

New High Resolution

Camera

FDSS Applications

FDSS Applications2

Living-cell PPI assay is based on BRET (Bioluminescent Resonance Energy Transfer) screening technology

Protein-Protein Interaction (PPI)

Publication: Application Note Nr. 25 (CBCS, Karolinska Institutet, University of Gothenburg)

Identification of small molecule modulators of reactive oxygen release in TNF-α primed primarx human neutrophils. In the test system freshly isolated primary human neutrophils are first incubated with TNF-α. The cells are then triggered with cytochalasin B. The superoxide anions produced are measured by a chemiluminescence technique based on isoluminol using the single photon counting camera of the Hamamatsu FDSS 7000.

Oxidative Stress Assay (ROS) Assays for measuring real time production of ROS (Reactive oxygen species) as an indicator of cell heath or signalling events

Energy Metabolism Assay (NADPH) NAD(P)H molecules are important cofactors for different enzymes involved in cellular pathways. Measurement of this molecule can determine metabolic activity for cells affected by disease.

Cell Health and Energy Metabolism

Addition of TNF-α/compound treated cells to pre heated Cytochalasin B (130 µl)

Recording signal for 5 minutes

Therapeutic area

Drug discovery

FDSS Screening technology

BRET1 (Rluc8) (96/384), BRET2 (96 format only), NanoBret (Promega), NanoBit (Promega)

Therapeutic area

Research & Clinical application � Inflammatory disease � Monitoring inflammation of transplant before surgery

� Cancer (drug evaluation studies for Chemotherapy

FDSS Screening technology

Amplex red (Thermofisher)/Luminol/ ROS-Glo (Promega) NADPH-Glo/Pholasin®-based ABEL® (Knight Scientific)

3FDSS Applications

Membrane potential activity hiPS-derived cardiomyocytes in 96 wells

Presentation 3rd FDSS application Workshop, Barcelona, Stephane Bedut (ICM, Servier)

Any acute drug effect involved in primary or human iPSC-derived cardiomyocytes can be detected by monitoring [Ca2+] transients and electrical activity.

Safety/Toxicology and Cardiovascular Disease

Application Note Pluricyte® Cardiomyocytes

Acquired 10 s (black) and 3 min. (red) after ouabain treatmenz (96 format, FluoVolt dye)

0.1 % DMSO

0:00 1:00

1 µM Diltiazem

0:00 1:00

1 µM Bay K 8644

0:00 1:00

100 nM E 4031

0:00 1:00

1 µM Nifedipine

0:00 1:00

100 nM Isoproterenol

0:00 1:00

A B CBaseline Isoproterenol (1 µM) E-4031 (1 µM)

10,000

5,000

0

RFU

0 20 40 60Time (sec)

0 20 40 60Time (sec)

0 20 40 60Time (sec)

Application Protocol iCell® Cardiomyocytes2Application Note COR.4U®

Therapeutic area

Drug discovery, Safety pharmacology (Cardiac & Neuron), Assessment of cardiotoxocity and drug efficacy early in drug development process

FDSS Screening technology

[Ca2+] sensitive dye (Cal520, ATT Bioquest)/Voltage sensitive dye (FluoVolt, Molecular probes)

Vehicle

Ivabradine 1 µM

Ivabradine 2 µM

Lidocaine 50 µM

Ivabradine 1 µM

1 s 1 s

1000

F.u

.

1000

F.u

.

Dia

stol

ic s

lope

(F.u

.s-1)

Lidocaine 50 µM 1000

800

600

400

200

0

FDSS Applications4

GPCRs (G-protein-coupled receptors) are one of the most important classes of drug targets

Effect of GPCR pathway activation: intracellular Ca2+, cAMP, Beta Arrestin

GPCR

Therapeutic area

Drug discovery

FDSS Screening technology

[Ca2+] sensitive dye (Cal520,ATT Bioquest)/Voltage sensitive dye (FluoVolt, Molecular probes), BRET, cAMP (Glow sensor,Promega), Beta Arrestin (Discoverx)

Print screen FDSS software

GPCR assay: � 1536 assay – Ca2+ Aequorin � B2-Arrestin 2 Recruitment

� Full agonist vs. partial agonist: w/o full view –> misleading

� Efficacy vs. AUC vs. Slow binders –> kinetics

� Time course is key

Cpd1Cpd2

Cpd3

125

100

75

50

25

0

-25

125

100

75

50

25

0

-25

-50

100

75

50

25

0

-25

-50

BRET

(% v

s D

opam

ine

1 µM

)

BRET

(% v

s D

opam

ine

1 µM

)

BRET

indu

ced

by c

ompo

unds

(% v

s D

opam

ine

1 µM

)

Log [ligand] (M)-10 -9 -8 -7 -6 -5

Publication: FDSS Application Nr. 23

The antagonist Haloperidol fully reverses the BRET signal induced by dopamine (a). The stimulation by dopamine is dose-dependent (b). Dopamine efficacy can be discriminated from other compounds activity (c).

(a) Antagonism (b) Dose-response (C) Efficacies DopamineEC50=7.3

Dopamine 1 µMHaloperidol 10 µM + Dopamine 1 µMHaloperidol 10 alone

Dopamine 1µMAripiprazole 1µMBifeprunox 1µMQuinpirole 1µM

Recording of Calcium transients using the Hamamatsu µCell: Response to neurotransmitter

(a)

Nor

mal

ized

to

base

line

fluor

esce

nce

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0.0

0 50 200100 250150 300

Time [s]

Thyrode solutionKClGlutamateNMDAAcetylcholineHistamineDopamineSerotoninATP

(b)Dopamine 1µMAripiprazole 1µMBifeprunox 1µMQuinpirole 1µM

Nor

mal

ized

to

base

line

fluor

esce

nce

1.4

1.2

1.0

0.8

0.6

0.4

0.2

0.01010.1 100

Concentration [µM]

GLutamateNMDAAcetylcholineDopamineSerotoninHistamineATP

Thyrode solution (negative control)KCl (positive control)

(a) Representative traces from calcium transients induced by various neuro-transmitters, KCl as positive control and thyrode solution as negative control are shown. The traces are normalized to the baseline fluorescence.

(b) The peak of calcium transients are calculated and plotted agaínst the neurotransmitter concentration.

5FDSS Applications

Publication: YFP-halide assays for CFTR drug discovery using the FDSS/µcell

Thierry Christophe, PhD, Director - Biology, Galapagos NV Hamamatsu 11th FDSS User Meeting 11 June 2015

Detection of CFTR potentiatorsCells over-expressing F508d-CFTR and YFP-H148/I152L

Fsk + inactive cpd

Fsk + CFTR potentiator

Cl-

Cl-

Cl-

l-

l-

NaI

Vehicle/inactive

CFTR potentiator

Dose response CFTR potentiator0.8

0.6

0.4

0.2

0.0

1.0

0.9

0.8

log conc (M)-12 -10 -8 -6 -4

1-F/

F0

F/F0

time

Ion Channel

(Isomerase Inhibitor Screening)

Use of a Real-Time Fluorescence Monitoring System for High-Throughput Screening for Prolyl Isomerase InhibitorsTadashi Mori, Selma Itami, Tomotaka Yanagi, Yota Tatara, Mari Takamiya and Takafumi Uchida

Enzymatic Assay

The Km value of CypA with the peptide was 59 M. (C) Concentration dependence of CsA inhibition of CypA activity. Concentrations of CypA and CsA are expressed as follows: CypA none, CsA none (♦); CypA 7 nM, CsA none ( ); CypA 7 nM, CsA 3.13 nM (x); CypA 7 nM, CsA 12.5 nM ( ); CypA 7 nM, CsA 50 nM, (▲);and CypA 7 nM, CsA200 nM (•).

CypA none, CsA noneCypA 7 nM,CsA noneCypA 7 nM, CsA 3.2 nM

Conv

ersi

on R

atio

(%)

100

80

60

40

20

-3 -2 -1 40 51 65 7 93 8 10

CypA 7 nM, CsA 12.5 nMCypA 7 nM, CsA 50 nMCypA 7 nM, CsA 200 nM

Antibody (Functional Assay)

Therapeutic area

Drug discovery (ion channel/GPCR)

FDSS Screening technology

Ca2+ dyeCalcium Mobilization response: Inhibition of Ca2+ response induced by EC80 of Agonist in presence of different antibodies

AntibodyCa2+ buffer only

80 nM Agonist

Therapeutic area:

Drug discovery

FDSS Screening technology

� Na+/K+ channel: TEFLAB dye, Membrane potential dye (Molecular device)/FluxOR Potassium Ion Channel Assay (Thermo Fisher)/SBFI (Thermo Fisher)/ FRET VSP dye (Invitrogen)

� Cl- channel Fluorescence of Yellow Fluorescent Protein mutant (YFP-H148Q/I521L) quenched by halides

l-

l-

FDSS Applications6

New Screening Technology

Therapeutic area

Cardiac, CNS, Muscular diseases

FDSS Screening technology

Ca2+ dye/(FDSS/μcell + EFS + High speed options)

High-Throughput Fluorescence Measurements of Ca2+ Transients in primary rat and in human iPSC-derived cardiomyocytes

a) Primary rat cardiomyocytes (Cosmo Bio) were cultured in 96-well plate. The above figures show the intracellular Ca2+ concentration changes for 5 s in 96 wells in a microplate. In primary cultured cardiomyocytes, cells in each well beat at different rates and with different timing (left). When electrical field stimulation was applied (1.0 Hz, voltage 5 V, duration 5 ms), the result was uniform Ca2+ oscillations between all wells resulting in synchronized beating of cells (right).

b) Effects of ion channel blockers on Ca2+ transients in iPS cardio-mocytes: Beating rate is dependent on Electric Field Stimulation frequency.

Spontaneous beating(a) Rat primary cardiomyocytes

Electric Field Stimulation (EFS) of human iPSC-derived neuron using Hamamatsu FDSS/µCELL

The Ca2+ response is inhibited in the presence of a calcium channel blocker, Bepridil

With 1.0 Hz stimulation

(b) Ca2+ channel blocker: Verapamil

Electric fieldStimulation (EFS)

96-channel electrode array

� Stimulate all 96 wells simultaneously � Cylindrical electrodes � Stimulation voltage is changeable column by column

Bepridil, a calcium channel blocker, was added to the wells at the indicated concentration and incubated for 20 min, and then EFS pulses (5 ms of pulse width, 40 Hz) were given. The figures on the right show intracellular Ca2+ concentration changes. At more than 15 µM, the Ca2+ response was completely inhibited. The IC50 value was estimated to be 5.6 µM (graph on the left).

Caution Notice: The FDSS/µCELL EFS system should not be used for optically detecting/monitoring change in transmembrane potential of the cells. The FDSS/µCELL EFS system should not be used on any cell or cells in which the user or anyone else has expressed target ion channels.

0

10

20

30

40

50

60

70

withoutstimulation

1.0H z astimulation

P ra

te [/

min

]

P rate [/min]

0

20

40

60

80

100

w/o 0.5Hz 1.0Hz 1.5Hz 2.0Hz

P ra

te [/

min

]

P rate [/min]

0

500

1000

1500

2000

2500

3000

3500

w/o 0.5Hz 1.0Hz 1.5Hz 2.0Hz

P-P

time

[mse

c.]

P-P time [msec.]

0

20

40

60

80

100

120

140

w/o 0.5Hz 1.0Hz 1.5Hz 2.0Hz

P ra

te [/

min

]

P rate [/min]

0

500

1000

1500

2000

2500

3000

3500

w/o 0.5Hz 1.0Hz 1.5Hz 2.0Hz

P-P

time

[mse

c.]

P-P time [msec.]

0

5

10

15

20

w/o 0.5Hz 1.0Hz 1.5Hz 2.0Hz

Risin

g slo

pe [/

mse

c.]

Rising slope

0

50

100

150

200

w/o 0.5Hz 1.0Hz 2.0Hz 3.0Hz

P ra

te [/

min

]

P rate [/min]

0

500

1000

1500

2000

w/o 0.5Hz 1.0Hz 2.0Hz 3.0Hz

P-P

time

[mse

c.]

P-P time [msec.]

0

50

100

150

200

250

w/o 0.5Hz 1.0Hz 2.0Hz 3.0Hz

IPW

D50

[mse

c.]

PWD50

0500

10001500200025003000350040004500

w/o 0.5Hz 1.0Hz 1.5Hz 2.0Hz

Ampl

itude

[RFU

]

Ampulitude

N=96

1.0 Hzstimulation

70

60

50

40

30

20

10

0

0.08

0.06

0.04

0.02

0.00

-0.02

10-6 10-5 10-4

withoutstimulation

P rate [/min]

P ra

te [/

min

]

Ampl

itude

(F/

F 0)

Bepridil [M]Time (s)

IC50=5.6 μM

3020100 3020100

0.1

0.05

0

3020100 3020100

Fluo

resc

ence

inte

nsity

(

F/F 0)

Presentation CDI 12th FDSS Users Meeting

iCell SkM + EarlyTox calcium dye

iCell Neurons

iCell Skeletal Myoblasts

Compound Treatment Electric Field Stimulation (EFS)

2V 3V 4V 5V 6V

7FDSS Applications

Rhodopsins: Light-gated ion channels

Optogenetic

Measurement 3D Cardiomyocyte (Spheroid)

Kuraray spheroid microplate (cardiomyocyte)

� 1 pixel around 1 spheroid � 1 pixel data showed Ca2+ oscillation of each spheroid.

Analyzed using Hamamatsu Software, AQUACOSMOS

New High Resolution Camera (“Well Analysis”)

Therapeutic area:

Drug discovery

FDSS Screening technology

� Detection system: Ca2+ sensitivite Fluo8 No Wash dye

� Stimulus: Depolarization induced by ChR2 activation with blue light pulses

Rhodopsins: Light-gated ion channels

ChR2(D156A)

� Target: human Cav1.3 (α1/α2δ1/β3) � Recipient cell line: HEK-293/kKir2.3 � Detection system: Ca2+ sensitive Fluo8 No Wash dye

� Stimulus: depolarization induced by ChR2 activation with blue light pulses

� Cav1.3 Blocker: Isradipine � HTS instrumentation: Hamamatsu FDSS/µcell

ChR2 induced membrane depolarization

Blue light(τ-off 6.9 min)

Other information: FDSS/µCell & FDSS7000

High Speed Acquisition & Fast Camera Option

Application: Enzymatic, Optogenetic, Cardiac assay...

Speed of acquisition: 200 Hz (96 well) 100 Hz (384 well)

High speedacquisition

1 s

www.hamamatsu.comE-mail: europe@hamamatsu.eu